Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01137032 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
A Phase 4 study of Atopic Dermatitis and Psoriasis, sponsored by Fougera Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
- 3
- Study locations
NCT01137032: Completed Phase 4 study of Atopic Dermatitis and Psoriasis, sponsored by Fougera Pharmaceuticals.
NCT01137032 is a Phase 4 study of Atopic Dermatitis and Psoriasis that has completed, run by Fougera Pharmaceuticals. The registered enrollment target is 19 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01137032, a Phase 4 study of Atopic Dermatitis and Psoriasis, has completed, sponsored by Fougera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic dermatitis involving greater than 20% body surface area.
Primary Outcome
The number of subjects with a post-injection serum cortisol level less than or equal to 18 ug/dL on Day 22.
Conditions Studied
Interventions
- DRUG Pandel Cream 0.1%
Study Locations (3)
Nebraska
- Christopher Huerter, MD - Omaha
South Carolina
- Oswald Mikell, MD - Hilton Head Island
Tennessee
- Michael Gold, MD - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-08 |
| Phase | Phase 4 |
What the finished NCT01137032 record still lists
NCT01137032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Pandel Cream 0.1% is the first listed.
NCT01137032 reports a single indexed study location in Nebraska, South Carolina, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01137032 about?
NCT01137032 is a clinical study titled "Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population". The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic dermatitis involving greater than 20% body surface area.
What is the current status of trial NCT01137032?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2004-06. Estimated completion is 2005-08.
What conditions does trial NCT01137032 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Psoriasis.
What interventions are being tested in trial NCT01137032?
The interventions under investigation include: Pandel Cream 0.1% (DRUG).
Who is sponsoring clinical trial NCT01137032?
This trial is sponsored by Fougera Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01137032 being conducted?
This trial has 3 study locations across Nebraska, South Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01137032's enrollment target sits among peer trials
19 140th of 150 higher than 10 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
RECRUITING · Phase 4
-
Molecular Signatures of Cutaneous Dupilumab Response
RECRUITING · Phase 4
-
Ethnic Differences in Mechanisms of Action of Dupilumab
RECRUITING · Phase 4
-
Dupixent and Narrowband UVB for Atopic Dermatitis
RECRUITING · Phase 4
-
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia